Quarter Ended November 2, 2019
Comparable sales decline of 3.9% on an owned basis; comparable sales decline of 3.5% on an owned plus licensed basis.
Diluted EPS of $0.01; $0.07 per share excluding restructuring and other costs.
For complete information regarding our financials, see our periodic filings.
Quarter Ended Nov 2, 2019